| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Agios Pharmaceuticals, Inc. (AGIO) has 10 insiders with recent SEC Form 4 filings, including 1 buy and 28 sells. AGIO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 149.1K | $5.31M | - | |
| Other | 67.7K | $2.41M | - | |
| CFO | 40.3K | $1.44M | - | |
| Other | 34.6K | $1.23M | - | |
| Dir | 17.8K | $634.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 20, 2017 | Cantley Lewis Clayton Jr. | Director | Sell | 9,000 | $56.36 | $507,260.00 | -1.3% | |
| Jul 7, 2017 | Biller Scott | Chief Scientific Officer | Sale+OE | 2,146 | $55.00 | $118,030.00 | -25.5% | |
| Jul 3, 2017 | Schenkein David P59 | Chief Executive Officer | Sale+OE | 3,000 | $51.18 | $153,540.00 | -100% | |
| Jun 21, 2017 | Biller Scott | Chief Scientific Officer | Sale+OE | 4,292 | $55.00 | $236,060.00 | -94.2% | |
| Jun 14, 2017 | Cantley Lewis Clayton Jr. | Director | Sell | 2,000 | $50.87 | $101,730.00 | -0.6% | |
| Jun 7, 2017 | Schenkein David P59 | Chief Executive Officer | Sale+OE | 3,000 | $50.02 | $150,060.00 | -100% | |
| May 25, 2017 | Cantley Lewis Clayton Jr. | Director | Sell | 2,036 | $47.10 | $95,885.42 | -0.6% | |
| May 1, 2017 | Schenkein David P59 | Chief Executive Officer | Sale+OE | 3,000 | $50.06 | $150,180.00 | -100% | |
| Apr 24, 2017 | Celgene European Investment Co LLC | 10% Owner | Buy | 624,575 | $49.50 | $30,916,462.50 | +50.7% | |
| Apr 18, 2017 | Cantley Lewis Clayton Jr. | Director | Sell | 5,090 | $54.37 | $276,753.48 | -0.9% |